TY - JOUR
T1 - Quarterly anti-vascular endothelial growth factor dosing for neovascular age-related macular degeneration
T2 - Real-world clinical outcomes
AU - Rusakevich, Alexander M.
AU - Zhou, Brenda
AU - Wong, Tien P.
AU - Wykoff, Charles C.
N1 - Funding Information:
Originally submitted March 22, 2019. Revision received May 15, 2019. Accepted for publication June 10, 2019. Dr. Wong reports grants for research support from Adverum, Neurotech, Opthea, Samsung, Allergan, Apellis, Clearside Biomedical, EyePoint (formerly pSivida), Regeneron, Novartis, Regenxbio, Santen, and Genentech/Roche outside the submitted work. Dr. Wykoff reports grants from Adverum, Neuro-tech, Opthea, and Samsung; personal fees from Bayer, PolyPhotonix, RecensMedical, Kodiak, Alimera Sciences, Allegro, Alnylam, DORC, Notal Vision, and ONL Therapeutics; and grants and personal fees from Allergan, Apellis, Clearside Biomedical, EyePoint (formerly pSivida), Regeneron, Novartis, Regenxbio, Santen, and Genentech/Roche outside the submitted work. The remaining authors report no relevant financial disclosures. Address correspondence to Charles C. Wykoff, MD, PhD, 6560 Fannin St., Suite 750, Houston, TX 77030; email: ccwmd@houstonretina.com. doi: 10.3928/23258160-20190905-17
Publisher Copyright:
© 2019 Slack Incorporated. All rights reserved.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019
Y1 - 2019
N2 - BACKGROUND AND OBJECTIVE: Characterize eyes managed with quarterly intravitreal anti-vascular endothelial growth factor injections for neovascular agerelated macular degeneration (nAMD). PATIENTS AND METHODS: Treatment-naïve nAMD eyes managed predominately using a treat-and-extend approach that received five or more consecutive quarterly injections from 2005 to 2017. RESULTS: One hundred fifty eyes were retrospectively identified. During quarterly dosing, a mean of 9.8 injections were given over a mean of 29 months. Ninetyone eyes (61%) had no exudative disease recurrence during quarterly dosing. Thirty-three eyes (22%) experienced exudative activity recurrence, with a mean cumulative yearly recurrence rate of 12% and a mean 6-letter loss of visual acuity (VA). Twenty-four eyes (16%) stopped quarterly treatments; nine (38%) of these subsequently experienced exudative activity recurrence with a mean 8-letter VA loss. CONCLUSION: In this real-world analysis of nAMD managed with quarterly dosing over a mean of more than 2 years' follow-up, 22% experienced disease recurrence during quarterly dosing, and 38% of eyes that stopped quarterly dosing experienced subsequent exudative disease recurrence.
AB - BACKGROUND AND OBJECTIVE: Characterize eyes managed with quarterly intravitreal anti-vascular endothelial growth factor injections for neovascular agerelated macular degeneration (nAMD). PATIENTS AND METHODS: Treatment-naïve nAMD eyes managed predominately using a treat-and-extend approach that received five or more consecutive quarterly injections from 2005 to 2017. RESULTS: One hundred fifty eyes were retrospectively identified. During quarterly dosing, a mean of 9.8 injections were given over a mean of 29 months. Ninetyone eyes (61%) had no exudative disease recurrence during quarterly dosing. Thirty-three eyes (22%) experienced exudative activity recurrence, with a mean cumulative yearly recurrence rate of 12% and a mean 6-letter loss of visual acuity (VA). Twenty-four eyes (16%) stopped quarterly treatments; nine (38%) of these subsequently experienced exudative activity recurrence with a mean 8-letter VA loss. CONCLUSION: In this real-world analysis of nAMD managed with quarterly dosing over a mean of more than 2 years' follow-up, 22% experienced disease recurrence during quarterly dosing, and 38% of eyes that stopped quarterly dosing experienced subsequent exudative disease recurrence.
UR - http://www.scopus.com/inward/record.url?scp=85072955081&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072955081&partnerID=8YFLogxK
U2 - 10.3928/23258160-20190905-17
DO - 10.3928/23258160-20190905-17
M3 - Article
C2 - 31589766
AN - SCOPUS:85072955081
SN - 2325-8160
VL - 50
SP - E250-E256
JO - Ophthalmic Surgery Lasers and Imaging Retina
JF - Ophthalmic Surgery Lasers and Imaging Retina
IS - 9
ER -